Novel therapy in the treatment of scleroderma

Research output: Contribution to journalArticle

Abstract

While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.

Original languageEnglish (US)
Pages (from-to)31-48
Number of pages18
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Penicillamine
Clinical Trials
4-Aminobenzoic Acid
Raynaud Disease
Proton Pump Inhibitors
Gastrointestinal Diseases
Colchicine
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Therapeutics
Quality of Life
Kidney
Pharmaceutical Preparations

Keywords

  • Angiotensin II inhibitors
  • Cytokines
  • D-penicillamine
  • Halofuginone
  • Inflammation
  • Minocycline
  • Pentoxifylline
  • Scleroderma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel therapy in the treatment of scleroderma. / Wigley, Fredrick; Sule, Sangeeta.

In: Expert Opinion on Investigational Drugs, Vol. 10, No. 1, 2001, p. 31-48.

Research output: Contribution to journalArticle

@article{d58ccfa4f2c94dcd87954fdefa7d2263,
title = "Novel therapy in the treatment of scleroderma",
abstract = "While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.",
keywords = "Angiotensin II inhibitors, Cytokines, D-penicillamine, Halofuginone, Inflammation, Minocycline, Pentoxifylline, Scleroderma",
author = "Fredrick Wigley and Sangeeta Sule",
year = "2001",
doi = "10.1517/13543784.10.1.31",
language = "English (US)",
volume = "10",
pages = "31--48",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Novel therapy in the treatment of scleroderma

AU - Wigley, Fredrick

AU - Sule, Sangeeta

PY - 2001

Y1 - 2001

N2 - While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.

AB - While the biology of the pathogenesis of scleroderma is continually being better understood, there still is no single agent or therapeutic combination that has a clear impact on the disease process. Traditional medications (colchicine, potassium aminobenzoate (potaba), D-penicillamine) are disappointing in clinical practice despite anecdotal evidence of benefit. Furthermore, the most popular traditional drug, D-penicillamine, failed to clearly show benefit when tested in a well-designed clinical trial comparing conventional high dose with a very low dose (125 mg po. q.i.d.) [1]. Currently, most success in managing scleroderma and improving quality of life is secondary to organ-specific therapy, such as management of a renal crisis with an ACE inhibitor, treatment of Raynaud's phenomenon with calcium channel blockers, or control of serious gastrointestinal reflux disease with a proton pump inhibitor. In this review we will focus on novel therapies that are currently being tested in the treatment of scleroderma and have the potential of modifying the disease process and overall clinical outcome. We have attempted to review the rationale for each agent, recognising that its true biological effect will only be determined in clinical trials.

KW - Angiotensin II inhibitors

KW - Cytokines

KW - D-penicillamine

KW - Halofuginone

KW - Inflammation

KW - Minocycline

KW - Pentoxifylline

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=0035186174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035186174&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.1.31

DO - 10.1517/13543784.10.1.31

M3 - Article

C2 - 11116279

AN - SCOPUS:0035186174

VL - 10

SP - 31

EP - 48

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -